PrIMAVeRa’s mathematical models and epidemiological repository may help illuminate areas previously obscured due to lack of information and provide an indication of which strategies (or combinations thereof) of vaccine and mAb implementation are most likely to result in the greatest benefit to public health.

​

In short, PrIMAVeRa may help public health officials and policymakers to reach the decisions resulting in the highest net benefit for public health, hopefully increasing investment in vaccine and mAb development, and preserving the last-resort antimicrobials currently available.